RT Journal Article
SR Electronic
T1 Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.17.20036640
DO 10.1101/2020.03.17.20036640
A1 Ni, Ling
A1 Ye, Fang
A1 Chen, Meng-Li
A1 Feng, Yu
A1 Deng, Yong-Qiang
A1 Zhao, Hui
A1 Wei, Peng
A1 Ge, Jiwan
A1 Li, Xiaoli
A1 Sun, Lin
A1 Wang, Pengzhi
A1 Liang, Peng
A1 Guo, Han
A1 Wang, Xinquan
A1 Qin, Cheng-Feng
A1 Chen, Fang
A1 Dong, Chen
YR 2020
UL http://medrxiv.org/content/early/2020/03/20/2020.03.17.20036640.abstract
AB The WHO has declared SARS-CoV-2 outbreak a public health emergency of international concern. However, to date, there was hardly any study in characterizing the immune responses, especially adaptive immune responses to SARS-CoV-2 infection. In this study, we collected blood from COVID-19 patients who have recently become virus-free and therefore were discharged, and analyzed their SARS-CoV-2-specific antibody and T cell responses. We observed SARS-CoV-2-specific humoral and cellular immunity in the patients. Both were detected in newly discharged patients, suggesting both participate in immune-mediated protection to viral infection. However, follow-up patients (2 weeks post discharge) exhibited high titers of IgG antibodies, but with low levels of virus-specific T cells, suggesting that they may enter a quiescent state. Our work has thus provided a basis for further analysis of protective immunity to SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe cases. It has also implications in designing an effective vaccine to protect and treat SARS-CoV-2 infection.Competing Interest StatementLN, YF, WP and CD have filed a provisional patent on the methodology of detecting SARS-CoV-2-specific antibody responses.Funding StatementThis work was supported in part by grants from Natural Science Foundation of China (NSFC, Grant No. 31991173 to CD), National key research (Grant No. 2016YFC130390 to LN) and an award from Zhejiang University Foundation (to CD).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available.